<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Claire</forename><surname>Schwab</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Wolfson Childhood Cancer Research Centre</orgName>
								<orgName type="laboratory">Leukaemia Research Cytogenetics Group</orgName>
								<orgName type="institution" key="instit1">Northern Institute for Cancer Research</orgName>
								<orgName type="institution" key="instit2">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karin</forename><surname>Nebral</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Children&apos;s Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">St Anna Kinderkrebsforschung</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lucy</forename><surname>Chilton</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Wolfson Childhood Cancer Research Centre</orgName>
								<orgName type="laboratory">Leukaemia Research Cytogenetics Group</orgName>
								<orgName type="institution" key="instit1">Northern Institute for Cancer Research</orgName>
								<orgName type="institution" key="instit2">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Leschi</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">INSERM Unit é Mixte de Recherch é 1131</orgName>
								<orgName type="institution" key="instit2">Institut Universitaire d&apos;H ématologie</orgName>
								<orgName type="institution" key="instit3">Universit é Paris Diderot</orgName>
								<address>
									<addrLine>Paris Sorbonne Cit é</addrLine>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">D épartement de G én étique</orgName>
								<orgName type="institution" key="instit1">H ôpital Robert Debr é</orgName>
								<orgName type="institution" key="instit2">Assistance Publique-H ôpitaux de Paris</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Esm</forename><forename type="middle">É</forename><surname>Waanders</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Human Genetics</orgName>
								<orgName type="institution" key="instit1">Radboud University Medical Center</orgName>
								<orgName type="institution" key="instit2">Radboud Institute for Molecular Life Sciences</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Judith</forename><forename type="middle">M</forename><surname>Boer</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology</orgName>
								<orgName type="institution">Erasmus MC-Sophia Children&apos;s Hospital</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Éta Žaliov</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Pediatrics</orgName>
								<orgName type="institution">University Hospital Schleswig-Holstein</orgName>
								<address>
									<settlement>Kiel</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Childhood Leukaemia Investigation Prague</orgName>
								<orgName type="department" key="dep2">Department of Pediatric Hematology/Oncology</orgName>
								<orgName type="department" key="dep3">Faculty of Medicine</orgName>
								<orgName type="institution">Charles University and University Hospital Motol</orgName>
								<address>
									<postCode>2nd</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosemary</forename><surname>Sutton</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Lowy Cancer Research Centre</orgName>
								<orgName type="institution" key="instit1">Children&apos;s Cancer Institute</orgName>
								<orgName type="institution" key="instit2">University of New South Wales</orgName>
								<address>
									<settlement>Sydney</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ingegerd</forename><forename type="middle">Ivanov</forename><surname>Öfverholm</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Clinical Genetics Section</orgName>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Molecular Medicine and Surgery</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kentaro</forename><surname>Ohki</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Pediatric Hematology and Oncology</orgName>
								<orgName type="institution">National Center for Child Health and Development</orgName>
								<address>
									<settlement>Tokyo</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yuka</forename><surname>Yamashita</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Nagoya Medical Center</orgName>
								<orgName type="institution">National Hospital Organization</orgName>
								<address>
									<settlement>Aichi</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefanie</forename><surname>Groeneveld-Krentz</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Division of Oncology and Hematology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Charit é-Universit ätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eva</forename><surname>Fro Ňkov</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Childhood Leukaemia Investigation Prague</orgName>
								<orgName type="department" key="dep2">Department of Pediatric Hematology/Oncology</orgName>
								<orgName type="department" key="dep3">Faculty of Medicine</orgName>
								<orgName type="institution">Charles University and University Hospital Motol</orgName>
								<address>
									<postCode>2nd</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marleen</forename><surname>Bakkus</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">Universitair Ziekenhuis Brussel</orgName>
								<orgName type="institution" key="instit2">Vrije Universiteit Brussel</orgName>
								<address>
									<settlement>Brussels</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joelle</forename><surname>Tchinda</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">Pediatric Oncology</orgName>
								<orgName type="department" key="dep2">Children&apos;s Research Centre</orgName>
								<orgName type="institution">University Children&apos;s Hospital Z ürich, Z ürich</orgName>
								<address>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thayana</forename><surname>Da Conceição Barbosa</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution" key="instit1">Pediatric Hematology-Oncology Program, Research Center</orgName>
								<orgName type="institution" key="instit2">Instituto Nacional de C âncer</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Grazia</forename><surname>Fazio</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Centro Ricerca Tettamanti</orgName>
								<address>
									<addrLine>Clinica Pediatrica</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Universit à di Milano-Bicocca</orgName>
								<address>
									<settlement>Monza</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wojciech</forename><surname>Mlynarski</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Pediatrics, Oncology, Hematology and Diabetology</orgName>
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Agata</forename><surname>Pastorczak</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Pediatrics, Oncology, Hematology and Diabetology</orgName>
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Giovanni</forename><surname>Cazzaniga</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution">Centro Ricerca Tettamanti</orgName>
								<address>
									<addrLine>Clinica Pediatrica</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Universit à di Milano-Bicocca</orgName>
								<address>
									<settlement>Monza</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">S</forename><surname>Pombo-De-Oliveira</surname></persName>
							<affiliation key="aff16">
								<orgName type="institution" key="instit1">Pediatric Hematology-Oncology Program, Research Center</orgName>
								<orgName type="institution" key="instit2">Instituto Nacional de C âncer</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>Trka</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Childhood Leukaemia Investigation Prague</orgName>
								<orgName type="department" key="dep2">Department of Pediatric Hematology/Oncology</orgName>
								<orgName type="department" key="dep3">Faculty of Medicine</orgName>
								<orgName type="institution">Charles University and University Hospital Motol</orgName>
								<address>
									<postCode>2nd</postCode>
									<settlement>Prague</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Kirschner-Schwabe</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Division of Oncology and Hematology</orgName>
								<orgName type="department" key="dep2">Department of Pediatrics</orgName>
								<orgName type="institution">Charit é-Universit ätsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="institution">German Cancer Consortium and German Cancer Research Center</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Toshihiko</forename><surname>Imamura</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Pediatrics</orgName>
								<orgName type="department" key="dep2">Graduate School of Medical Science</orgName>
								<orgName type="institution">Kyoto Prefectural University of Medicine</orgName>
								<address>
									<settlement>Kyoto</settlement>
									<country key="JP">Japan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gisela</forename><surname>Barbany</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Clinical Genetics Section</orgName>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Department of Molecular Medicine and Surgery</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stanulla</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Pediatric Hematology and Oncology</orgName>
								<orgName type="institution">Medical School Hannover</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andishe</forename><surname>Attarbaschi</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Pediatric Hematology and Oncology</orgName>
								<orgName type="institution">St Anna Children&apos;s Hospital</orgName>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Renate</forename><surname>Panzer-Gr</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Children&apos;s Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">St Anna Kinderkrebsforschung</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roland</forename><forename type="middle">P</forename><surname>Kuiper</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Human Genetics</orgName>
								<orgName type="institution" key="instit1">Radboud University Medical Center</orgName>
								<orgName type="institution" key="instit2">Radboud Institute for Molecular Life Sciences</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Monique</forename><forename type="middle">L</forename><surname>Den Boer</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Pediatric Oncology</orgName>
								<orgName type="institution">Erasmus MC-Sophia Children&apos;s Hospital</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">Dutch Childhood Oncology Group</orgName>
								<address>
									<addrLine>The Hague</addrLine>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Él Ène Cav</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">INSERM Unit é Mixte de Recherch é 1131</orgName>
								<orgName type="institution" key="instit2">Institut Universitaire d&apos;H ématologie</orgName>
								<orgName type="institution" key="instit3">Universit é Paris Diderot</orgName>
								<address>
									<addrLine>Paris Sorbonne Cit é</addrLine>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="laboratory">D épartement de G én étique</orgName>
								<orgName type="institution" key="instit1">H ôpital Robert Debr é</orgName>
								<orgName type="institution" key="instit2">Assistance Publique-H ôpitaux de Paris</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anthony</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Wolfson Childhood Cancer Research Centre</orgName>
								<orgName type="laboratory">Leukaemia Research Cytogenetics Group</orgName>
								<orgName type="institution" key="instit1">Northern Institute for Cancer Research</orgName>
								<orgName type="institution" key="instit2">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><forename type="middle">J</forename><surname>Harrison</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Wolfson Childhood Cancer Research Centre</orgName>
								<orgName type="laboratory">Leukaemia Research Cytogenetics Group</orgName>
								<orgName type="institution" key="instit1">Northern Institute for Cancer Research</orgName>
								<orgName type="institution" key="instit2">Newcastle University</orgName>
								<address>
									<settlement>Newcastle upon Tyne</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sabine</forename><surname>Strehl</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Children&apos;s Cancer Research Institute</orgName>
								<orgName type="institution" key="instit2">St Anna Kinderkrebsforschung</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">7CF18763D0179DE38FE325D6600BEC00</idno>
					<note type="submission">Submitted 14 March 2017; accepted 30 May 2017. DOI 10.1182/ bloodadvances.2017006734.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:51+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy, characterized by a wide spectrum of genetic abnormalities, which are used in risk stratification for treatment. 1</s><s>4]<ref type="bibr" target="#b4">[5]</ref> Germline PAX5 mutations also occur in familial ALL. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s>]<ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref> Here we present a subset of patients with BCP-ALL lacking the major cytogenetic abnormalities (ETV6-RUNX1, BCR-ABL1, and TCF3-PBX1 fusions, high hyperdiploidy, near-haploidy, low hypodiploidy, MLL rearrangements, or intrachromosomal amplification of chromosome 21) 1 with intragenic amplifications of PAX5 (PAX5 AMP ).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Patients in this study originated from 15 international study groups.</s><s>All participating centers obtained local ethical committee approval and written informed consent in accordance with the Declaration of Helsinki.</s><s>Diagnosis of BCP-ALL was confirmed by immunophenotyping, according to standard criteria.</s><s>Demographic and clinical details are summarized in supplemental Table 1.</s></p><p><s>4]<ref type="bibr" target="#b14">[15]</ref> Thirteen PAX5 AMP samples were processed on SNP6.0 or CytoScan HD arrays (Affymetrix, Santa Clara, CA; supplemental Methods).</s><s>Fluorescence in situ hybridization (FISH), using PAX5 locus-specific probes, was carried out on 26 cases (supplemental Figures <ref type="figure" target="#fig_3">1 and 2</ref>).</s></p><p><s>Survival analysis considered event-free survival, defined as time to relapse, and overall survival, defined as time to death, both censored at last contact.</s><s>Very early relapse was defined as within 18 months of diagnosis, early relapse as .18</s><s>months and #6 months after the end of treatment, with late relapse defined as occurring .6 months posttreatment.</s><s>Survival rates were calculated using the Kaplan-Meier method and compared using univariate Cox regression models.</s><s>All analyses were performed using Intercooled Stata 14.0 (Stata, College Station, TX).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results and discussion</head><p><s>PAX5 AMP was identified in 79 patients with BCP-ALL, at diagnosis in 77 cases; only relapse material was available from 2 patients (Figures <ref type="figure" target="#fig_3">1 and 2A</ref>).</s><s>The amplified region encompassed exons 2 and 5</s></p><formula xml:id="formula_0">1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -2 2 1 0 -1 -<label>2</label></formula><p><s>36.6Mb 36.8Mb</s><s>(n 5 68), exon 5 only (n 5 9), or exon 2 only (n 5 2), encoding the DNA-binding and octapeptide domains (Figure <ref type="figure" target="#fig_2">1</ref>).</s><s>The extent of PAX5 AMP identified by MLPA was confirmed by single-nucleotide polymorphism arrays (n 5 13; Figure <ref type="figure" target="#fig_2">1B</ref>; supplemental Figure <ref type="figure">3</ref>; GEO database accession number GSE99813).</s><s>Amplification of the exons identified by MLPA was validated by quantitative genomic polymerase chain reaction (n 5 18; data not shown), as previously described. <ref type="bibr" target="#b14">15</ref></s><s>ecause this MLPA approach did not target PAX5 exons 3 and 4, the extent of the amplified region in cases with exon 2 or 5 amplification remains unknown.</s><s>Several patients with PAX5 AMP also presented with deletions (n 5 8) and gains (3-4 copies; n 5 9) of other PAX5 exons (Figure <ref type="figure" target="#fig_3">2</ref>).</s><s>The same amplification was present in 9 matched diagnosis and relapse samples (Figure <ref type="figure" target="#fig_3">2B</ref>).</s><s>FISH analysis excluded the presence of PAX5 rearrangements and confirmed that the amplification was located within the PAX5 locus (supplemental Figure <ref type="figure" target="#fig_3">2</ref>).</s><s>Whether PAX5 AMP results in expression of structurally mutant PAX5 proteins or loss of function remains to be determined.</s></p><p><s>Although sporadic cases with PAX5 AMP have been previously reported, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17</ref> here we show PAX5 AMP to be a recurrent abnormality, occurring in 52 of 5535 patients from population-based cohorts (;1% of BCP-ALL and 3% of the B-other subgroups [33 of 1271] supplemental Table <ref type="table">2</ref>).</s><s>The remaining 27 patients were recruited individually to this study.</s><s>Apart from 1 patient case with BCR-ABL1 fusion, PAX5 AMP was mutually exclusive of other major risk-stratifying cytogenetic markers, 1 including IGH, PDGFRB/CSF1R, ABL1, ABL2, JAK2, and ZNF384 rearrangements, among 24 patient cases tested by FISH (data not shown).</s></p><p><s>Among the other genes assessed by MLPA, CDKN2A/B loss was the most common abnormality associated with PAX5 AMP (82%), higher than in other BCP-ALL subgroups. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b17">18</ref></s><s>Gain of EBF1 (26%), deletion of IKZF1 (13%), and deletion of the PAR1 region resulting in P2RY8-CRLF2 fusion (10%) were other common alterations, suggesting a collaborative role in PAX5 AMP leukemia development.</s></p><p><s>Consistent with the MLPA data, chromosomal abnormalities involving chromosome arm 9p (26%), trisomy 5 (23%), and monosomy 7 (12%) were observed among patients with successful karyotypes (n 5 57; supplemental Table <ref type="table">3</ref>).</s><s>Notably, trisomy 5 is a rare finding in BCP-ALL in the absence of high hyperdiploidy.</s><s>Our previous study of trisomy 5 as the sole cytogenetic abnormality suggested an association with poor prognosis. <ref type="bibr" target="#b18">19</ref></s><s>e main demographic and clinical features of the 77 patients with PAX5 AMP identified at diagnosis were male predominance (66%), age .10 years (25%), white blood cell count (WBC) $50 3 10 9 (39%), and National Cancer Institute high-risk status (55%).</s><s>Minimal residual disease (MRD) data were available for 45 patients.</s><s>Among ALL2003  patients with evaluable MRD (n 5 8), 50% were positive at day 28 (.0.01%).</s><s>Among patients treated in ALL-BFM 2000 with MRD data (n 5 14), 12 were classified as MRD intermediate risk and 1 each as high and low risk, whereas all European Organisation for Research and Treatment of Cancer patients (n 5 10) were intermediate risk, apart from 1 classified as high risk.</s><s>From these limited data, we cannot assign an association between PAX5 AMP and MRD.</s></p><p><s>Among 74 patients with complete remission data available, 73 achieved complete remission by end of induction; 1 patient died before therapy.</s><s>Relapse occurred in 40% (29 of 73) of these patients.</s><s>The site of relapse, known for 22 patients, was isolated bone marrow (n 5 16), extramedullary (n 5 3), or combined relapse (n 5 3).</s><s>The time to relapse (median, 2.1 years) was known for 25 patients, with a ratio of very early to early to late relapse of 9:10:6, classifying 15 (55%) as high risk according to current criteria. <ref type="bibr" target="#b19">20</ref></s><s>Among patients experiencing relapse with sufficiently long follow-up, 17 (59%) died (relapse, n 5 9; infection in remission, n 5 3; unknown, n 5 5), and 10 remained alive .3 years postrelapse.</s></p><p><s>The 5-year EFS and OS rates, evaluable for 74 patients, were 49% (95% confidence interval [CI], 36%-61%) and 67% (95% CI, 54%-77%), respectively.</s><s>To identify risk factors, we examined the effects of age, WBC, National Cancer Institute status, year of diagnosis, and presence of additional genetic abnormalities, but only WBC was significant.</s><s>Patients with a WBC .50 3 10 9 /L had a significantly increased risk of death (hazard ratio, 3.48; 95% CI, 1.46-8.32;</s><s>P 5 .005).</s><s>In context, these low survival rates were generated from patients diagnosed over a 22-year period (1993-2015), treated according to a wide range of trial protocols, highlighting the need for prospective studies.</s></p><p><s>The clinical, genetic, and outcome profiles of patients with PAX5 AMP were distinct from those harboring PAX5 deletions, which occur at different incidences between BCP-ALL subgroups. <ref type="bibr" target="#b2">3</ref></s><s>Although present at an increased frequency in high-risk ALL, PAX5 deletions are not associated with an inferior outcome. <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22</ref></s><s>Because the number of patients with BCP-ALL with distinct PAX5 fusions is limited, their prognostic relevance remains to be determined.</s></p><p><s>In conclusion, we have identified a rare subset of patients with BCP-ALL with PAX5 AMP , who share a distinct spectrum of genetic abnormalities, including high frequencies of CDKN2A/B loss and trisomy 5.</s><s>A majority of these patients lack established cytogenetic abnormalities, suggesting that PAX5 AMP may define a distinct subtype of BCP-ALL.</s><s>Although several patients presented with P2RY8-CRLF2 and 1 with BCR-ABL1, both have been reported as secondary changes occurring alongside primary genetic abnormalities. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref></s><s>Where matched diagnosis and relapse samples were available, the same amplification was present at both time points, indicating that PAX5 AMP may be an important driver of leukemogenesis.</s><s>Because patients with PAX5 AMP showed a high incidence of relapse, we recommend testing for PAX5 AMP in future ALL trials to determine its true prognostic impact.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>MLPA and SNP6.0 profiles of patients with PAX5 AMP .</s><s>(A) Example of MLPA results using the P335 IKZF1 MLPA kit.</s><s>The plot shows the probe ratio for each target contained in the kit (EBF1, 4 probes; IKZF1, 8 probes; CDKN2A/B, 3 probes; PAX5, 6 probes; ETV6, 6 probes; BTG1, 4 probes; RB1, 5 probes; and the PAR1 region, CRLF2, CSF2RA, and IL3RA, 1 probe each).</s><s>Probe ratio values between 0.75 and 1.3 were considered to be within the normal range, equivalent to the normal copy number of 2. Values ,0.75 or .1.3</s><s>indicated loss or gain, respectively, and a value ,0.25 indicated biallelic loss.</s><s>These values correspond to copy numbers of 1, 3 and 4, and 0, respectively.</s><s>A value $2.0 corresponds to a copy number of $4 and was interpreted as amplification.</s><s>Approximate copy numbers of amplified exons ranged from 4 to 22 (median, 5.86).</s><s>Ratio values of 1 representative patient (patient 64) showing amplification of PAX5 encompassing exons 2 and 5, gain of EBF1 consistent with trisomy 5 in this patient, monoallelic loss of IKZF1, and biallelic loss of CDKN2A/B.</s><s>(B) Copy number profiles (log2ratio) of the PAX5 locus of 8 patients with PAX5 AMP processed on the SNP6.0 array.</s><s>*In patient 79, PAX5 amplification was identified at relapse with no material available from diagnosis.</s><s>**Patient 60 shows amplification of exon 5 only and gain of exons 1 to 4. (C) Exon and protein structure of PAX5; the amplified region encodes the DNA-binding paired domain and the octapeptid motif.</s><s>PD, paired DNA-binding domain (amino acids 16-142); O, octapeptide (aa 179-186); H, homeodomain (aa 228-254); TA, transactivation domain (aa 304-391); I, inhibitory domain (aa 359-391).</s></p></div></figDesc><graphic coords="2,79.79,225.93,266.10,272.18" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Genetic features of patients with PAX5 AMP .</s><s>(A) Data for the 77 patients with intragenic amplification of PAX5 identified at diagnosis.</s><s>The copy numbers for each PAX5 exon and the other genes targeted by the P335 IKZF1 MLPA kit are shown.</s><s>Cytogenetic results were available for 57 patients, with abnormalities involving the short arm of chromosome 9, trisomy 5, and monosomy 7 being the most common recurrent chromosomal abnormalities.</s><s>†In patient 31, the probe ratio values for exons 2 and 5 were just below the cutoff of 2 for $4 copies; because the percentage of blast cells was low at 83.5%, this result was interpreted as amplification.</s><s>‡In patient 69, MLPA showed that exon 2 had a ratio of 2.42 and exon 5 of 1.69; however on the single-nucleotide polymorphism array, exons 2 to 5 were amplified.</s><s>(B) Data from 9 matched diagnosis-relapse pairs.</s><s>*In patient 37, the difference in copy number of the amplified exons between diagnosis and relapse was due to reduced percentage of blasts at relapse.</s><s>**P2RY8-CRLF2 fusion assessed by MLPA, FISH, and/or reverse-transcriptase polymerase chain reaction.</s><s>***Patient 16 presented with partial trisomy of chromosome 5 as a result of an unbalanced translocation involving chromosomes 1 and 5: 47,XY,der(1)(1qter-1p21::5q?34-5qter),1der(5)(5pter-5q15::1p21-1pter).</s></p></div></figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="22"> AUGUST 2017  x VOLUME 1, NUMBER<ref type="bibr" target="#b18">19</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="22"> AUGUST 2017  x VOLUME 1, NUMBER<ref type="bibr" target="#b18">19</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="22">AUGUST 2017 x VOLUME 1, NUMBER 19 INTRAGENIC PAX5 AMPLIFICATION IN BCP-ALL 1475</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="22"> AUGUST 2017  x VOLUME 1, NUMBER<ref type="bibr" target="#b18">19</ref> </note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="22">AUGUST 2017 x VOLUME 1, NUMBER 19 INTRAGENIC PAX5 AMPLIFICATION IN BCP-ALL 1477</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>This work was supported by Bloodwise (formerly Leukaemia and Lymphoma Research) and the Anniversary Fund of the Austrian National Bank (OeNB grant 14133) (K.N.).</s><s>M.Z., E.F., and J.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authorship</head><p><s>Contribution: C.S., K.N., S.S., and C.J.H. designed the study; C.S., L.C., K.N., S.S., C.J.H., and A.V.M. analyzed and interpreted data; the remaining authors provided genetic and clinical data; and all authors approved the final manuscript.</s></p><p><s>Conflict-of-interest disclosure: The authors declare no competing financial interests.</s></p><p><s>The current affiliation for E.W. and R.P.K. is Princess M áxima Center for Pediatric Oncology, Utrecht, The Netherlands.</s></p><p><s>A list of the members of the International Berlin-Frankfurt-M ünster (I-BFM) Study Group appears on the I-BFM website (https:// bfminternational.wordpress.com/).</s><s>ORCID profiles: R.S., 0000-0002-0188-6005; K.O., 0000-0003-2838-4555; E.F., 0000-0002-6900-8145; J. Tchinda, 0000-0002-9450-2006; G.F., 0000-0001-7077-8422; G.C., 0000-0003-2955-4528; J. Trka, 0000-0002-9527-8608; H.C., 0000-0003-2840-1511; S.S., 0000-0002-0179-0628.</s></p><p><s>Correspondence: Sabine Strehl, Children's Cancer Research Institute, St Anna Kinderkrebsforschung, Zimmermannplatz 10, 1090 Vienna, Austria; e-mail: sabine.strehl@ccri.at;</s><s>and Christine J. Harrison, Leukaemia Research Cytogenetics Group, Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Level 6, Herschel Building, Newcastle-upon-Tyne NE1 7RU, United Kingdom; e-mail: christine.harrison@newcastle.ac.uk.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Rev</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="123" to="135" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Pax5: a master regulator of B cell development and leukemogenesis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Medvedovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tagoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Busslinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunol</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="179" to="206" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1081" to="1088" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Mullighan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Goorha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Radtke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">446</biblScope>
			<biblScope unit="issue">7137</biblScope>
			<biblScope unit="page" from="758" to="764" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study</title>
		<author>
			<persName><forename type="first">Den</forename><surname>Boer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Van Slegtenhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Menezes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">X</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="125" to="134" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Schrader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Waanders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1226" to="1231" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G.A. Leukemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Auer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gombert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1136" to="1138" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Coyaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Struski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="3089" to="3097" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nebral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Denk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Attarbaschi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="134" to="143" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kurahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hayakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miyata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1822" to="1830" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Functional heterogeneity of PAX5 chimeras reveals insight for leukemia development</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fortschegger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Anderl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Denk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Strehl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="595" to="606" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cazzaniga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Palmi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="992" to="995" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mendioroz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="295" to="304" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL</title>
		<author>
			<persName><forename type="first">A</forename><surname>Van Der Veer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Waanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pieters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2622" to="2629" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Morrison</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1104" to="1113" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study</title>
		<author>
			<persName><forename type="first">J</forename><surname>Familiades</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bousquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lafage-Pochitaloff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1989" to="1998" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols</title>
		<author>
			<persName><forename type="first">I</forename><surname>Ofverholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heyman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1936" to="1939" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sulong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Irving</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="100" to="107" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Is trisomy 5 a distinct cytogenetic subgroup in acute lymphoblastic leukemia?</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Martineau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Genet Cytogenet</title>
		<imprint>
			<biblScope unit="volume">148</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="159" to="162" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Relapsed childhood acute lymphoblastic leukaemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bhojwani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Pui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="e205" to="e217" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Moorman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Enshaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schwab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1434" to="1444" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Children&apos;s Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Mullighan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">360</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="470" to="480" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">BCR-ABL1 gene rearrangement as a subclonal change in ETV6-RUNX1-positive B-cell acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Dun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vanhaeften</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Batt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Diano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Williamson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Adv</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="132" to="138" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL</title>
		<author>
			<persName><forename type="first">M</forename><surname>Morak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Attarbaschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fischer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="5134" to="5142" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
